KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Raw Materials (2017 - 2023)

Biolife Solutions (BLFS) has disclosed Raw Materials for 8 consecutive years, with $23.7 million as the latest value for Q1 2023.

  • On a quarterly basis, Raw Materials rose 42.37% to $23.7 million in Q1 2023 year-over-year; TTM through Mar 2023 was $23.7 million, a 42.37% increase, with the full-year FY2022 number at $21.0 million, up 21.44% from a year prior.
  • Raw Materials was $23.7 million for Q1 2023 at Biolife Solutions, up from $21.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $23.7 million in Q1 2023 to a low of $1.3 million in Q3 2019.
  • A 5-year average of $10.3 million and a median of $7.5 million in 2020 define the central range for Raw Materials.
  • Biggest YoY gain for Raw Materials was 504.27% in 2021; the steepest drop was 6.12% in 2021.
  • Biolife Solutions' Raw Materials stood at $3.0 million in 2019, then fell by 4.16% to $2.9 million in 2020, then soared by 504.27% to $17.3 million in 2021, then increased by 21.44% to $21.0 million in 2022, then increased by 13.04% to $23.7 million in 2023.
  • Per Business Quant, the three most recent readings for BLFS's Raw Materials are $23.7 million (Q1 2023), $21.0 million (Q4 2022), and $18.2 million (Q3 2022).